Convenient dosing schedule every 12 weeks after 2 starter doses at Weeks 0 and 4.
FOR STELARA® (ustekinumab)
Janssen CarePath helps your patients start and stay on STELARA® that you've prescribed.
A LEGACY IN THE TREATMENT OF PLAQUE PSORIASIS
STELARA® has been clinically studied for 19 years1*
More than 8000 dermatologists have prescribed STELARA® in the United States1†‡
More than 300,000 adult patients with moderate to severe plaque psoriasis treated with STELARA® in the United States1§
STELARA® has an estimated cumulative exposure of 1,600,000 patient-years worldwide since launch1║
NATIONAL PSORIASIS FOUNDATION®
Recognized STELARA® as a first-line systemic in moderate to severe plaque psoriasis.2**††
*A phase 1 clinical trial of STELARA® was initiated in 2001 in patients with moderate to severe plaque psoriasis. Phase 3, double-blind, placebo-controlled, multicenter trials PHOENIX 1 and PHOENIX 2 began in 2005 and 2006, respectively.
†IQVIA-Xponent data. Dermatologists who have written at least 1 prescription for STELARA® in the United States from July 2017 to August 2019.
‡Reflects usage across all lines of therapy.
§More than 300,000 adult patients treated with STELARA® in the United States from September 2009 to December 2019. Estimations are based on calculations using product-utilization data collected in the United States for STELARA® to determine patient type, average dose per administration, total number of administrations, and patient persistency rates.
║Based on worldwide estimated number of patient-years from launch through December 2019. Patient-years were estimated by calculations using STELARA® distribution data to determine average yearly dose while considering regional estimates of patient compliance to dosing regimen.
Reference: 1. Data on file. Janssen Biotech, Inc.